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LETTER
Ribavirin is effective against drug-resistant
H7N9 inﬂuenza virus infections
Dear Editor,
In February and March 2013, a novel inﬂuenza A (H7N9)
virus emerged in China, causing an acute respiratory dis-
tress syndrome and occasionally multiple organ failure with
high fatality rates in humans (Li et al., 2014). A total of 681
laboratory-conﬁrmed cases and 275 deaths have been
reported as of November 13th, 2015, with a fatality rate of
40% (http://www.who.int/inﬂuenza/human_animal_interface/
HAI_Risk_Assessment/en/). H7N9 has been evolving and
established amongst chickens in China over the past two
years with occasional human infections (Lam et al., 2015; Su
et al., 2015), thus posing a threat to public health. In the
absence of an annually-updated effective vaccine, antiviral
drugs constitute the ﬁrst line of defense against H7N9
infections. H7N9 viruses already possess natural resistance
to M2-ion channel blockers (amantadine and rimantadine)
when it ﬁrst emerged in 2013 (Gao et al., 2013). Therefore
neuraminidase inhibitors (NAIs), which include oseltamivir
(TamiﬂuH), zanamivir (RelenzaH) and peramivir constitute
the main antiviral drugs against H7N9 infections (Hu et al.,
2013; Wu et al., 2013). However, treatment with NAIs
against H7N9 infections has resulted in the emergence of
drug-resistant mutant viruses, as soon as 1∼9 days after
administration (Gao et al., 2013; Hu et al., 2013). Moreover,
the ﬁrst H7N9 isolate (A/Shanghai/1/2013(H7N9), SH-H7N9)
was resistant to oseltamivir (Gao et al., 2013).
It is therefore necessary to investigate whether other
classes of drugs can control H7N9 infections. A recent study
shows that the RNA polymerase 2 (PB2) gene of the H7N9
virus is critical for virulence in mammals (Bi et al., 2015).
Ribavirin is a well-characterized, broad-spectrum nucleoside
inhibitor used to halt the synthesis and capping of viral RNA
and mRNA, respectively, by the viral RNA-dependent RNA
polymerase (Crotty et al., 2000). Ribavirin is approved for
treating infections with Hepatitis C virus and respiratory
syncytial virus (Graci and Cameron, 2006). Moreover, rib-
avirin is effective by itself or in combination with NAIs and/or
M2-ion channel blockers against H1N1, H3N2 and H5N1
inﬂuenza infections (Smee et al., 2005; Ilyushina et al., 2008;
Nguyen et al., 2009). Here, we want to investigate whether
ribavirin is effective by itself against H7N9 virus infections,
especially to virus mutants that have developed resistance to
NAIs. To compare the efﬁcacy of ribavirin to that of NAIs,
zanamivir was used as a positive control.
To determine the effectiveness of the ribavirin against
H7N9 viruses in vitro, NAI-sensitive (A/Anhui/1/2013, AH-
H7N9) and -resistant (SH-H7N9) viruses were used in this
study. The 50% effective virus-inhibitory concentration
(EC50) value was used to evaluate the antiviral functions of
ribavirin. Serial two-fold dilutions of ribavirin were used to
test the EC50 against AH-H7N9 and SH-H7N9 on Madin-
Darby Canine Kidney (MDCK) epithelial cells, respectively.
The results showed that ribavirin was effective against both
AH-H7N9 and SH-H7N9 with an EC50 of 0.01∼0.02 mg/mL
(3∼4 nmol) (Table 1), implying that ribavirin could be utilized
against both NAI-sensitive and -resistant H7N9 viruses. In
addition, the ribavirin at a dose of ∼300 folds of the calcu-
lated EC50 is also safe in vitro without signiﬁcant cytotoxicity.
In vitro studies showed that the ribavirin is effective to
both the NAI-sensitive (AH-H7N9) and -resistant (SH-H7N9)
viruses. To further study antiviral function in vivo, the efﬁcacy
of ribavirin against H7N9 infection was then tested in a
mouse animal model. To conﬁrm the antiviral functions of
ribavirin, zanamivir was selected as a positive drug control.
The survival, percentage weight change and clinical symp-
toms in the animals after challenge were monitored over the
courseof theexperiment (14days).All animals infectedwithAH-
H7N9 displayed rufﬂed fur, loss of activity and body weight loss
beginning 2 days post-infection (d.p.i.). Mice treated with pla-
cebo did not survive and had weight loss of over 35% (Fig. 1A
and 1B). Mice treated with ribavirin or zanamivir also experi-
enced weight loss of up to around 30%, but all mice in each
group gradually recovered and survived (Fig. 1A and 1B). In
general, the clinical signs of mice in the ribavirin and zanamivir
groupsweremilder than thatof theplacebogroup.Nosigniﬁcant
changes were observed frommice in the mock-infection group.
Five mice from each group were euthanized at 3 d.p.i. and
the lung virus titers (LVTs) were test in MDCK cells, with the
results presented as 50% tissue culture infective dose
(TCID50). The results showed that the LVTs from mice trea-
ted with either the ribavirin or zanamivir were 10-fold lower
than that of the sterile phosphate-buffered saline (PBS)
placebo group (P < 0.5) (Fig. 1C). Interestingly, ribavirin-
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treated mice displayed lower LVTs than that of zanamivir-
treated animals, but the values were not statistically signiﬁ-
cant (P > 0.5) (Fig. 1C).
In conclusion, ribavirin displayed antiviral activities com-
parable to zanamivir against H7N9 virus infections in vitro
and in vivo, and the data support the use of ribavirin against
NAI-resistant H7N9 virus infections. Since it had been shown
in previous studies that SH-H7N9 containing the NAI-
Table 1. EC50 values of ribavirin against H7N9 virus
Viruses Ribavirin (±SD)
mg/mL Effective dose (nmol)
AH-H7N9 0.0166 (±0.0029) 3.3964 (±0.5864)







































































Figure 1. Efﬁcacy of ribavirin in mice infected with AH-H7N9. Mice (n = 9) were given ribavirin, zanamivir or PBS (placebo) twice
daily, respectively. Animals were inoculated i.n. with 10× LD50 of AH-H7N9 in 50 µL PBS at one day after the initiation of treatment,
and an untreated group was mock-challenged with an equal volume of PBS as control. Survival and body weights were monitored
daily over a 14-day observation period and expressed as percentages of the initial values (A). The mortality rate was calculated from
the survival curve of each group (B). Five mice from each group were euthanized at 3 d.p.i. LVTs were quantiﬁed in MDCK cells, and
expressed as log10 TCID50/0.1 mL (C). The data are presented as the mean ± SD. Statistical analysis on the LVTs were performed
with a paired-sample t-test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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resistant K224 mutation (H3 numbering) on the neu-
raminidase (NA) gene reverts back to the NAI-sensitive
R224 mutation in vivo (Yen et al., 2014), as well as the rel-
atively lower replication ability in vitro compared to AH-H7N9
(the NAI-sensitive virus) (Wu et al., 2013), only AH-H7N9
was used for the studies in mice.
Notably, administration of ribavirin via the intranasal (i.n.)
route was still efﬁcacious against severe inﬂuenza virus
infections without any of the negative side effects associated
with oral or intravenous administration (Gilbert and McLeay,
2008). The present study showed that the i.n. route is also
effective in the case of ribavirin against H7N9 virus infection.
Human infections with H7N9 mainly originate from contact
with infected poultry or contaminated materials in live poultry
markets (Gao, 2014), and administration of ribavirin into the
nasal mucosa would be an effective strategy to mitigate the
risk of H7N9 infections in humans.
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